Answers are grounded in this paper and cite their sources.
Review evaluates suzetrigine's efficacy in managing pain and its potential as a non-opioid alternative, suggesting significant therapeutic promise.
Introduction and purpose: Pain, especially chronic, remains a major public health burden, often refractory to existing treatments and associated with significant individual and social costs. Recent advances in our understanding of voltage-gated sodium channels, particularly NaV1.8, have highlighted their pivotal role in nociceptive signal transmission in peripheral sensory neurons. Suzetrigine, a novel and highly selective NaV1.8 inhibitor, has emerged as a promising therapeutic candidate in this context. Aim: This review aims to evaluate the efficacy, safety, and therapeutic potential of suzetrigine, a novel and selective NaV1.8 channel inhibitor, in pain management and to assess its role as a non-opioid alternative in modern pain treatment. Materials and Methods: A comprehensive review of literature available in the PubMed database was performed. This process involved a thorough search of articles written in English containing the following key terms: “suzetrigine”, “selective voltage-gated sodium channels”, “pain”, “pain management”, “NaV1.8”. The gathered data was then scrupulously examined and analyzed. Conclusion: Suzetrigine with its high NaV1.8 channel selectivity and robust acute pain efficacy may represent a breakthrough in analgesia and pain management strategies. By minimizing off-target effects commonly associated with non-selective sodium channel blockers, suzetrigine offers a compelling alternative to opioids in treatment of postoperative pain. Its role in chronic and neuropathic pain remains under active investigation, with promising but not yet definitive results.
No takes yet. Share an insight, caveat, or question.
Krzyżanowska et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: